Eyestem Research

Current cell and gene therapy products are estimated to cost >$250k per injection. This is unsustainable. Our vision is to democratize access to cell therapy and provide benefits to a larger section of humanity We intend to disrupt the global cell therapy ecosystem and set a new benchmark for quality and affordability in this sector. Eyecyte-RPE-our flagship project to treat incurable macular degeneration has excellent efficacy results and will be in FIM trials in 2021.